

(Rel. 77-10/98 Pub.605)

FORM 6-3

Pra titi ner' D k t No. 2605/102

IN THE UNITED STATES PATENT AND TRADEMARK O

Patent application	00/296 C
of	8
Invento	or(s)
for	
Title of inv	vention

OR

In re application of: Miyata, T.

Application No.: 10/009,877 Group Art Unit: Not Assigned Filed: November 13, 2001 Examiner: Not Assigned

For: **BLOOD CARBONYL COMPOUND -TRAPPING AGENT**

Commissioner for Patents Washington, D.C. 20231

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS OF FILING OR BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. § 1.97(b))

NOTE: "An information disclosure statement shall be considered by the Office if filed by the applicant. (1) within three months of the filing date of a national application; (1) within three months of the date of entry of the national stage as set forth in § 1.491 In an International application; or (3) before the mailing date of a first Office action on the merits, whichever event occurs last." 37 CF.R. § 1.97(b)

CERTIFICATE of MAILING/TRANSMISSION (37 C.F.R. § 1.8(a))

I hereby certify that this correspondence is, on the date shown below, being:

MAILING

deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date: August 6, 2002

FACSIMILE

☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Robert M. Asher

(type or print name of person certifying)

(Transmittal of Information Disclosure Statement Within Three Months of Filing or Before Mailing of First Office Action [6-3]--page 1 of 2) NOTE: The "filing date of a national application" under 37 C.F.R. § 1.97(b) has two possible meanings. Where the filing is a direct one to the United States Patent & Trademark Office, the filing is defined in 37 C.F.R. § 1.53(b) as "the date on which: (1) A specification containing a description pursuant to § 1.71 and at least one claim pursuant to § 1.75; and (2) any drawing required by § 1.81(a), are filed in the Patent and Trademark Office in the name of the actual inventor or inventors as required by § 1.41." 37 C.F.R. § 1.97(b)(1). On the other hand, an international application that enters the national stage occurs when the applicant has filed the documents and fees required by 35 U.S.C. § 371(c) within the periods set forth in § 1.494 or § 1.495. 35 U.S.C. § 371(c) requires the filing of the following: (1) the basic national fee; (2) a copy of the international application, unless already sent by the International Bureau, and optionally an English translation if fled in another language; and, also optionally (3) amendments under PCT Article 19, with a translation into English if made in another language; (4) an oath or declaration; and (5) a translation into English of any annexes to the international preliminary examination report, if such annexes were made in another language. The optional items must be submitted later, with surcharges. 37 C.F.R. § 1.97(b)(2).

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. § 1.97(b).

NOTE: "No certification or fee is due when the filing Is made within the above time period. It is advisable to ensure that no Office action has been mailed if the disclosure statement is delayed until after three months from filing."

NOTE: "An information disclosure statement will be considered to have been filed on the day it was received in the Office, or on an earlier date of a mailing if accompanied by a properly executed certificate of mailing under 37 C.F.R. 1.8, or Express Mail certificate under 37 C.F.R. 1.10. An Office action is mailed on the date Indicated in the Office action." Notice of April 20, 1992 (1138 O.G. 37-41, 39).

NOTE: "The term national application' Includes continuing applications (continuations, divisions, continuationsin-part) so three-months will be measured from the actual filing date of an application as opposed [sic] to the effective date of a continuing application." Notice of April 20, 1992 (1138 O.G. 37-41, 39).

NOTE: "An action on the merits means an action which treats the patentability of the claims in an application, as opposed to only formal or procedural requirements. An action on the merits would, for example, contain a rejection or indication of allowability of a claim or claims rather than just a restriction requirements (37 CF.R. 1.142) or just a requirement for additional fees to have a claim considered (37 C.F.R. 1.16(d)). Thus, if an application was filed on Jan. 1 and the first Office action on the merits was not mailed until six months later on July 1, the examiner would be required to consider any proper information disclosures statement filed prior to July 1." Notice of April 20, 1992 (1138 O.G. 37-41, 39).

WARNING: "A petition for suspension of action to allow applicant time to submit an information disclosure statement will be denied as failing to present good and sufficient reasons, since 37 C.F.A. § 1.97 provides adequate recourse for the timely submission of prior art for consideration by the examiner.' Notice of July 6, 1992 (1141 O.G. 63).

Reg. No.: 30,445

Signature of Practitioner

Tel. No.: 617/443-9292

Robert M. Asher

Bromberg & Sunstein LLP

Customer No.: 00-2101

125 Summer Street, Boston, MA 02110

Pra titi ner's D ket N . 2605/102

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent application		
of		
	Inventor(s)	
for		
٦	Fitle of invention	
	OR	
In re application of: Miyata, T.		CEIVED UG 1 4 2002 ENTER 1600/2900
Application No.: 10/009,877 Filed: November 13, 2001 For: BLOOD CARBONYL COMPOUND T	Group Art Unit: Not Assigned Examiner: Not Assigned RAPPING AGENT	
Commissioner for Patents Washington, D.C. 20231		
SUPPLEMENTAL INFORM	MATION DISCLOSURE STAT	EMENT
(When using Express Mail, th	DER 37 C.F.R. § 1.8(a) and 1.10* ne Express Mail label number is mandate ail certification is optional.)	ory;
I hereby certify that this correspondence is, on the	e date shown below, being:	
deposited with the United States Postal Serv Washington, D.C. 20231	MAILING rice in an envelope addressed to the Cor	nmissioner for Patents,
37 C.F.R. § 1.8(a)	37 C.F.R. § 1.10*	
with sufficient postage as first class mail.	☐ as "Express Mail Post Office t Mailing Label No	
□ transmitted by facsimile to the Patent and Trace Date: August 6, 2002	RANSMISSION demark Office. Signature	le
	Robert M. Asher	ing)

(Information Disclosure Statement [6-1]--page 1 of 7)

NOTE: "An information disclosure statement shall be considered by the Office if filed by the applicant within any one of the following time periods:

- (1) Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d);
- (2) Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application;
- (3) Before the mailing date of a first Office action on the merits; or
- (4) Before the mailing date of a first Office action after the filing of a request for continued examination under § 1.114."

37 C.F.R. § 1.97(b).

NOTE: "Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section." 37 C.FR. § 1.56(a).

"Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:

- (1) each inventor named in the application;
- (2) each attorney or agent who prepares or prosecutes the application; and
- (3) every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application." 37 C.F.R. § 1.56(c).

NOTE: The "duty as described in § 1.56 will be met so long as the information in question was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98 before issuance of the patent." Notice of January 9, 1992, 1135 O. G. 13 -25 at 17.

WARNING: "No information disclosure statement maybe filed in a provisional application." 37 C.FR. § 1.51(d).

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement: (check sections forming a part of this statement: discard unused sections and number pages consecutively)

- 1. Preliminary Statements
- 2. FORMS PTO/SB/08A and 08B (formerly FORM PTO-1449)
- 3.

 Statement as to Information Not Found in Patents or Publications
- 4. ☐ Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted
- 5.

 Cumulative Patents or Publications
- 6. Copies of Listed Information Items Accompanying This Statement
- 7. Concise Explanation of Non-English Language Listed Information Items
 - 7A.

 EPO Search Report
- 8. Translation(s) of Non-English Language Documents
- 9. Concise Explanation of English Language Listed Information Items (Optional)
- 10. Identification of Person(s) Making This Information Disclosure Statement

(complete the following, if appropriate)

Sections

, respectively, have been continued on ADDED PAGE(S).

NOTE: "Once the minimum requirements are met the examiner has an obligation to consider the information." Notice of April 20, 1992 (1138 O.G. 37-41, 37).

(Information Disclosure Statement [6-1]--page 2 of 7)

S cti n 1. Pr liminary Stat m nts

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

Section 2. Forms PTO/SB/08A and 08B (formerly Form PTO-1449)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Miyata, T.

Attorney Docket:

2605/102

Serial No:

10/009,877

Art Group Unit:

Not Assigned

Date Filed:

Invention:

Art Group Unit: Not Assigned Filed: November 13, 2001 Examiner Name: Not Assigned htion: BLOOD CARBONYL COMPOUND TRAPPING AGENT LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENTS

International Patents

Examiner Initials	Number	Number Number	Issue Date	Inventor	Class/Subclass
	AM	WO 01/24790	2001 April 12	Miyata	A61K 31/155
Evaniman C	i an atuma.				
Examiner S	ignature:				
Date Consid	dered:		_		
			or not citation is in conformed. Include copy of this		
					02605/00102 212017.1

S cti n 6. C pi f Li ted Informati n It m Accompanying Thi Statement

NOTE: 37 C.F.R. § 198(a)(2) requires that any information disclosure statement filed under § 1.97 shall include:

"A legible copy of .:

- (i) Each U.S. patent application publication and U.S. and foreign patent;
- (ii) Each publication or that portion which caused it to be listed,
- (iii) For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or that portion of the application which caused it to be listed including any claims directed to that portion. . .

Legible copies of all items listed in Forms PTO/SB/08A and 08B (formerly Form PTO-1449) accompany this information statement.

(complete the following, if applicable)

Exception(s) to above:

Items in prior application, from which an earlier filing date is claimed for this application, as identified in Section 4.
Cumulative patents or publications identified in Section 5.

S ction 8. Translati n(s) f N n-English Languag D cum nts

- NOTE: "If a written English language translation of a non-English language document, or portion thereof, is within the possession, custody or control of, or is readily available to any individual designated in § 1.56(c), a copy of the translation shall accompany the statement." 37 C.F.R. § 1.98(c).
- NOTE: "The Office does not intend to require translations unless they have been reduced to writing and are actually translations of what is contained in the non-English language information. Applicants should note, however, that most examiners do not have the ability to understand information which is not in English and that the Office will not routinely translate information submitted in a non-English language. The examiner will consider the information insofar as it is understood on its face, e.g., drawings, chemical formulas, English language abstracts, but will not have the information translated unless it appears to be necessary to do so. Applicants are required to aid the examiner by complying with the requirements for a concise explanation in § 1.98(a)(3) for information submitted in a non-English language." Notice of January 9, 1992, 1135 O.G. 13-25, at 21.
- NOTE: "The examiner will indicate that the non-English language information has been considered in the same manner as consideration is indicated for information submitted in English." Notice of April 20, 1992 (1138 O.G. 37-41, 41).
 - Submitted herewith is an English translation of the following foreign language patents, publications or information or of those portions of those patents, publications or information considered to be material:

Japanese patent number WO 01/24790 published April 12, 2001 and listed in Section 2 as Ref. No. AM.

(complete the following, if applicable)

No English language translations of the foreign language patents, publications or

information or parts thereof are readily available, except for those listed above.
The following foreign language documents submitted are believed to be the equivalent or substantial equivalent of the English language documents identified below, which are also submitted herewith.

Secti n 10. Id ntificati n of Pers n(s) Making This Informati n **Disclosure Statement**

The person making this statement is			
	(check each applicable item)		
(a) 🗆 the inve	ntor(s) who signs bel	ow .	
		·	
		SIGNATURE OF INVENTOR	
		(type or print name of inventor who is signing)	
(b) ☐ an individual associated with the filing and prosecution of this application (37 C.F.R. § 1.56(c))			
		SIGNATURE OF INVENTOR	
		(type or print name of inventor who is signing)	
(c) = the practi	tioner who signs belo	ow on the basis of the information:	
	(check each a	oplicable item)	
	supplied by the inve	entor(s).	
	supplied by an indiv of this application. (3	idual associated with the filing and prosecution 37 C.F.R. § 1.56(c))	
•	in the practitioner's f		
Reg. No.: 30,445		SIGNATURE OF PRACTITIONER	
Tel. No.: 617/443-9292		Robert M. Asher (type or print name of person certifying)	
Customer No.: 00-2101		Bromberg & Sunstein LLP 125 Summer Street, Boston, MA 02110	

(Information Disclosure Statement-Section 10. Identification of Person(s) Making This Information Disclosure Statement [6-1]-page 7 of 7)